Search
Brigatinib
go.drugbank.com/drugs/DB12267ApprovedInvestigationalBrigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). … [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexVoxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease.
MM-093
go.drugbank.com/drugs/DB05512InvestigationalMM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults … Research on AFP suggests that it may play a role in modulating the immune system of the mother in order to protect the developing fetus during pregnancy.
Lucinactant
go.drugbank.com/drugs/DB04897ApprovedLucinactant is a new synthetic peptide-containing surfactant for intratracheal use. … It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol, POPG) and a fatty acid (palmitic acid).
Marstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigational[L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant. … Marstacimab is a human monoclonal immunoglobulin G Type 1 (IgG1) antibody produced by Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Sodium lauryl sulfoacetate
go.drugbank.com/drugs/DB13157ApprovedWithdrawnSodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
DG051
go.drugbank.com/drugs/DB05177ExperimentalDG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. … DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
Gold
go.drugbank.com/drugs/DB14154InvestigationalA yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. … Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
Mixtures: Medi SM 24K Gold Hydrogel Peptide Mask PackTridecactide
go.drugbank.com/drugs/DB15687Investigational[A203210] Tridecactide, along with [metenkefalin], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877] … Tridecactide, also known as alpha-corticotropin 1-13, is a deacetylated and deaminated alpha-melanocyte stimulating hormone, which may have antipyretic, anti-inflammatory, and antimicrobial effects.